



ATTENTION: BOX AFTER FINAL  
RESPONSE UNDER 37 C.F.R. § 1.116  
EXPEDITED PROCEDURE REQUESTED  
EXAMINING GROUP 1653

PATENT  
Customer No. 22,852  
Attorney Docket No. 02481.1693

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

HABERMANN et al.

Application No.: 09/664,326

Filed: September 18, 2000

For: SIGNAL SEQUENCES FOR  
PREPARING LEU-HIRUDIN BY  
SECRETION BY E. COLI INTO  
THE CULTURE MEDIUM

Group Art Unit: 1653

Examiner: H. Schnizer

Assistant Commissioner for Patents  
Washington, DC 20231

Sir:

AMENDMENT AFTER FINAL

In reply to the Final Office Action of January 7, 2003, and pursuant to  
37 C.F.R. § 1.116, Applicants propose that this application be amended as follows:

IN THE CLAIMS:

Please cancel claims 1 to 5 and 10 to 14, and amend claims 6, 8 and 9 as  
follows:

Claim 6. (Twice Amended) A process for selecting a [suitable] signal peptide for  
secretory expression of a desired hirudin or hirudin derivativ protein in *E. coli*,  
comprising:

(a) expressing [expression] in *E. coli* in culture medium, hirudin or a  
hirudin derivative which has antithrombotic activity, and which has a defined amino

OK TO  
ENTER  
HS 4-23-03

CJ

# 14  
And H/C  
AF  
4/15/03

RECEIVED  
APR 09 2003  
TECH CENTER 1600/2900